FDA approves neoadjuvant/adjuvant nivolumab for resectable …
WEB1 day ago · Linkedin. On October 3, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by ...
FDA Approves Presurgical, Postsurgical Opdivo for NSCLC
WEB1 day ago · The FDA has approved Opdivo as a presurgical and postsurgical treatment for some patients with non-small cell lung cancer. The Food and Drug Administration (FDA) has approved neoadjuvant (presurgical) Opdivo (nivolumab) with platinum-doublet chemotherapy followed by postsurgical single-agent Opdivo for adults with resectable (removable by ...
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
WEB22 hours ago · Opdivo, a programmed death receptor-1 (PD-1) blocking antibody, is also approved for the following NSCLC indications: Adults with resectable (tumors ≥4cm or node positive) NSCLC in the ...
Perioperative Opdivo Extends Event-Free Survival in Lung Cancer
WEB1 day ago · Patients with resectable non-small cell lung cancer (NSCLC) who received perioperative Opdivo (nivolumab) demonstrated significantly extended event-free survival (EFS) compared with placebo. The improvement in EFS was observed in both patients who achieved a pathologic complete response (PCR) and …
Nivolumab NSCLC Approval Expanded to Perioperative Setting
WEB21 hours ago · Nivolumab NSCLC Approval Expanded to Perioperative Setting. Sharon Worcester, MA. October 03, 2024. 0. The US Food and Drug Administration (FDA) has expanded the approval of nivolumab (Opdivo ...
U.S. Food and Drug Administration Approves Opdivo® …
WEBMar 7, 2024 · U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients …
FDA approves neoadjuvant nivolumab and platinum-doublet …
WEBOn March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell...
FDA approves nivolumab in combination with cisplatin and …
WEBOn March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult...
U.S. Food and Drug Administration Approves Opdivo® …
WEBOct 14, 2023 · Bristol Myers Squibb today announced that Opdivo ® was approved by the U.S. Food and Drug Administration for the adjuvant treatment of adult and pediatric patients 12 years and older with ...
Opdivo (nivolumab) in Combination with Cisplatin-Based …
WEBJul 11, 2023 · Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.